Daniel Lippis, CVP d’Edwards Lifesciences, cède des actions pour 54.168$
Read the full article on Investing.com →
KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.
KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.